Las Vegas, NV, Feb 07, 2023 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces a Community-Based Partnership (CBP) with the David R. Metcalf Invisible Wounds Foundation, a non-profit organization that advances brain health care for active duty military and veterans by addressing traumatic brain injury (TBI) and suicide prevention among Naval Special Warfare...

Las Vegas, NV, January 12, 2023 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote. Chemical warfare using organophosphate nerve agents is a threat worldwide. The risk could not be higher for civilians and military personnel operating in conflict areas like Ukraine. Nerve...

Las Vegas, NV, December 19, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today presents a Company update and recap of its product development programs. The Company has medical products in development which it intends to move forward in their respective clinical programs with the goal of FDA submission and commercialization. “We are extremely pleased with the progress our...

Las Vegas, NV, November 23, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today presents a Company update and recap of its concussion drug development program. Concussions represent an ‘unmet’ medical need and affect tens of millions worldwide. Odyssey acquired the intellectual property and all rights to the concussion drug in March 2021. Since the acquisition, Odyssey...

Las Vegas, NV, November 15, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced it plans to  hold the Annual Meeting of Stockholders of Odyssey Health, Inc. on January 12, 2023. To be considered at the annual meeting, any stockholder proposals must be received at the principal executive offices of the Company, 2300...

Las Vegas, NV, November 03, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, is pleased to announce its continued commitment to the newly formed entity, Odyssey NeuroPharma, with the expansion of its executive team. Joining the executive team at Odyssey NeuroPharma to advance Odyssey’s concussion treatment, and Niemann-Pick...

Las Vegas, NV, November 01, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), announces that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As announced, Odyssey’s recently completed Phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. Odyssey designed the Nasal Device with...

Las Vegas, NV, October 11, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the formation of Odyssey Neuropharma, Inc., a wholly owned subsidiary, focused on developing drugs to treat neurological disorders. The blood-brain barrier (BBB) represents a significant obstacle for drug delivery to the brain. Many drugs have failed in neuroscience research due to the...

Las Vegas, NV, October 6, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today presents a recap of their concussion drug development program. Concussions represent an ‘unmet’ medical need and affect millions worldwide. Repetitive concussions can increase the risk of developing Chronic Traumatic Encephalopathy (CTE) and other neuropsychiatric disorders. Odyssey acquired...

Las Vegas, NV, Sept. 30, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing a unique drug to treat concussion has decided to dissolve its sports advisory board. The sports advisory members have been outspoken advocates for concussion prevention and for the importance of finding responsible treatments. We created the advisory board to increase awareness of our mission to bring a much-needed pharmaceutical for a...

Las Vegas, NV, Sept. 28, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces the completion of all cohorts for its Phase I Single Ascending Dosing (SAD) and Multiple Ascending Dosing (MAD) clinical trial. Odyssey’s trial involved administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Throughout the trial, the drug was...

Las Vegas, NV, Sept. 13, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for the second cohort of their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects to determine drug safety. For...

  Las Vegas, NV, August 18, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For MAD Cohort I, the drug was safe and well...

  Las Vegas, NV, August 10, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial. Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. MAD Cohort I subjects were dosed for five...

  Las Vegas, NV, August 04, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, is pleased to announce the launch of its new innovative corporate website: https://www.odysseyhealthinc.com/. The new corporate website, like the Company’s previously announced name change, was designed to not only better reflect Odyssey Health’s mission and focus, but also improve communication...

  Las Vegas, NV, July 12, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well tolerated. Concussions...

  Las Vegas, NV, June 29, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Data from Cohort II indicates that the drug was safe and well-tolerated. The trial is...

  Las Vegas, NV, June 08, 2022 -- McapMediaWire -- RedChip Companies will air a new C-Level interview with Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International on The RedChip Money Report® on Bloomberg TV, this Saturday, June 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the US. RedChip’s CEO Dave Gentry interviews Odyssey’s CEO Michael Redmond in this exclusive interview, covering the questions on the mind of...

  IRVINE, CA, June 01, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort I of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For Cohort I, the drug was safe and well tolerated. Concussions represent an ‘unmet’ medical...

  IRVINE, CA, May 5, 2022 -- McapMediaWire -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their Phase I clinical trial. Odyssey’s trial is administering PRV-002, their novel drug to treat concussion, to healthy human subjects. Thus far the drug has shown to be safe and well tolerated. Each year, there...

  IRVINE, CA, April 20, 2022 -- McapMediaWire -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing a proprietary drug compound to treat concussion, is honored to welcome Vice Admiral (r) Timothy Szymanski to the Company’s prestigious Military Advisory Board. Odyssey’s drug candidate, PRV-002 is currently in a phase 1 clinical trial. “Too many service members and veterans are suffering...

  IRVINE, CA, March 31, 2022 -- McapMediaWire -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced the formation of its Military Advisory Board with the appointment of prestigious leaders in the field. Garnering experience and insight from these leaders in our military service branches will provide critical insight to traumatic brain injuries and the effects it has on those...